PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving letrozole together with lapatinib before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This randomized phase II trial is studying how well giving letrozole together with
lapatinib works in treating postmenopausal women with stage I, stage II, or stage III breast
cancer that can be removed by surgery.